Microbot Medical's LIBERTY System Wins Surgical Robotics Industry Award — Microbot Medical Inc.

Event summary

Microbot Medical's LIBERTY® Endovascular Robotic System won the Innovative Start-Up Award from Surgical Robotics Technology (SRT) on June 25, 2026.
LIBERTY is the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures.
The system has seen continued adoption and increased utilization since its Full Market Release in early April 2026, now being used at leading academic centers across multiple U.S. states.

The big picture

Microbot Medical's award highlights the growing recognition of its innovative technology in the surgical robotics sector. The LIBERTY System's FDA clearance and expanding adoption reflect a broader industry shift towards minimally invasive, precision-driven endovascular solutions. As competition intensifies, Microbot's ability to scale its commercial strategy will be critical for maintaining market leadership.

What we're watching

Adoption Pace: The pace at which the LIBERTY System gains traction in leading academic centers will determine its market penetration and competitive positioning.
Regulatory Compliance: How Microbot Medical navigates ongoing geopolitical risks, particularly those affecting Israel, could impact its operational stability and future growth.
Competitive Differentiation: Whether the LIBERTY System can sustain its unique value proposition as the only FDA-cleared single-use robotic system in peripheral endovascular procedures.